

BIOHIT OYJ:n SHAREHOLDERS' ASSEMBLY 2020

Osmo Suovaniemi, Chairman of the Board

Dear shareholders of Biohit Oyj,

I warmly welcome you all to attend this shareholders' meeting of the company, which under these exceptional circumstances, is arranged using virtual connections.

Coronavirus pandemic has caused exceptional amount of global fear, anxiety and panic. Until to date, some 28 million people have got infected and about 0.9 million infected have died.

As compared with the global figures, the situation in Finland is reasonably good, the numbers of persons lost due to coronavirus pandemic have been relatively small in our country. Altogether, Finland has reported altogether 339 persons died of the infection, which translates to approximately 2 persons every day.

Although coronavirus is a serious concern, I would pay your attention in this talk also to another serious issue, gastric- and esophageal cancer. As a company taking community accountability, Biohit has done serious work and several innovations aiming to a timely detection of the risks of these cancers, and the patient would receive appropriate treatment, compatible with more favorable disease outlook.

Worldwide, there are 1.6 million new cases of gastric and esophageal cancers diagnosed every year, and 1.3 million patients die of these diseases annually. In Finland, 700 patients die of gastric and esophageal cancer, while around 1000 new patients are being diagnosed every year, which means approximately 2 deaths per day.

Unlike coronavirus infection, there is no hope to reduce these cancer deaths by vaccines, but the only way to achieve this is

- 1) early detection of the cancer risks in the primary diagnosis of dyspeptic complaints and reflux symptoms as well as in the health monitoring of elderly people in particular
- 2) screening, for both of which an opportunity is offered by our GastroPanel innovation, providing substantial amount of added diagnostic information and producing cost savings.

The fear and anxiety associated with corona, with panic and use of divergent protective measures has caused a major depression in our economy, non-voluntary leaves of employees, unemployment as well as an unmeasurable amount of human suffering.

This is in contrast to gastric and esophageal cancer, that in most cases are asymptomatic, and thus do not arouse fear, because in Finland

1. the measures to be used in the primary diagnosis offered by the national management guidelines fail to disclose the risk factors of these cancers before alarming symptoms develop, and in addition

2. there is no population-based national screening program for early detection of the risks of these cancers.

Once these alarming symptoms have appeared, the treatment response is poor or the disease has frequently progressed beyond reach of a curative therapy. I will return to this issue later.

In our company, we are lucky in that the employees in our company as well as in the daughter companies in Italy and the UK have stayed healthy so far. In the mid of March 2020, the majority of the personnel was moved in part to work in distance at home.

Despite the fact that due to coronavirus pandemic, the turnover of the company declined by 40% and our gross margin was deficient by 1.0 MEUR during the first half of 2020, there has been no need to lay off temporarily the personnel.

Instead of the lay-offs, we have designed a new international marketing strategy, particularly for GastroPanel, including the promotion of the sales of the other products, so as to compensate the deficit due to the reduced sales of all products during the first half of the year.

What does the company have for sale at the moment?

As a result of the significant community-responsible investments and active patenting strategy of Biohit Oyj, a series of products have been completed, all based on several innovations of the company.

Among these products designed for an unmet global need, increasing patient safety and contributing to primary prevention of diseases, include the following innovations: GastroPanel, ColonView-FIT and Acetium-series of products as well as to these products several important complementary products and services.

The globally unique GastroPanel blood test and the GastroSoft software application that interprets the test results, is the first-line diagnostic test for patients suffering from upper abdominal complaints or reflux symptoms. GastroPanel testing that produces significant added diagnostic information and helps saving health care costs is also recommended for screening of the gastric- and esophageal cancer risks.

When is GastroPanel blood test indicated?

1. Among the dyspeptic and reflux patients, the unique GastroPanel® – Helicobacter test diagnoses

- *Helicobacter pylori* -infection
- Atrophic gastritis (gastric mucosal atrophy and dysfunction) and its location in antrum and/or corpus
- Level of gastric acid output. Continuous high acid output predisposes to oesophageal reflux disease, with associated ulcerative oesophagitis, Barrett's oesophagus and lower oesophageal cancer

2. To increase the patient safety and spare health care costs, for all those suffering from dyspepsia and reflux symptoms, as well as for the routine health control of asymptomatic subjects, it is

recommended to use GastroPanel as the first-line diagnostic test before gastroscopy, if the patient does not have alarming symptoms.

- Gastroscopy with biopsies is felt unpleasant by most subjects, is an expensive procedure, and among the subjects with dyspepsia and reflux symptoms, it frequently discloses only a normal gastric mucosa.

- GastroPanel in the primary diagnosis and in screening helps in timely finding of the patients for whom gastroscopy, treatment and follow-up are indicated.

3. In contrast to GastroPanel, the commonly used helicobacter tests (UBT and SAT) i) do not detect atrophic gastritis (injury of stomach mucosa), and in addition, ii) may give false negative helicobacter results, and iii) do not provide any information about the status of gastric acid output.

- Without correct diagnosis of helicobacter and/or timely detected atrophic gastritis, - patients may develop disease and even decease of gastric and esophageal cancer or due to complications of helicobacter-induced peptic ulcer disease.

- Atrophic gastritis is the major course of vitamin-B12 deficiency and possibly its accompanied sequels, such as peripheral neuropathy, depression and dementia. Every fourth woman and every tenth male shall die of dementia. This difference is explained in part by the fact that women live longer than men.

- Atrophic gastritis may also cause malabsorption of magnesium, zinc and some medications, as well as calcium deficiency with subsequent osteoporosis and bone fractures, or iron deficiency with divergent complications.

4. Along with the aging population, vitamin-B12-, calcium- and iron deficiency have become a constantly increasing national health burden. Vitamin B12-deficiency can also be associated with vascular thrombotic complications, which according to recently published studies, are particularly confined to patients with more severe coronavirus infection.

5. Without early detection, atrophic gastritis (acid-free stomach) can cause severe infections of the gastrointestinal and respiratory tract, particularly among elderly people, which are frequently fatal particularly among hospitalized patients.

At present, even the leading clinical laboratory in the country (HUSLAB) lists in its test manual the following indications for GastroPanel use:

- The tests are being used in the diagnostic algorithm of the patients with abdominal symptoms,
- for diagnosing helicobacter infection, as well as
- in early detection of atrophic gastritis

<http://www.huslab.fi/Tutkimusohjekirja> with search: helicobakteeri: 20609 fP-Mabi-La fP-Mahalaukun biomerkkiainetutkimus, laaja

The following conditions detected by GastroPanel:

- i) symptomatic helicobacter infection after eradication therapy,
 - ii) atrophic gastritis, or
 - iii) symptomatic high acid output, which can predispose to esophageal reflux disease or lower esophageal cancer,
- are all indications of gastroscopy and biopsy examination.

In this setting, GastroPanel-diagnosis and screening help in timely detection of the patients who need gastroscopy, treatment or follow-up.

The primary prevention of diseases particularly among the elderly people would promote longer endurance in the daily work and consequently, more healthy elderly people would need less nursing and less nurses than at present.

In addition, it is important to notice that acid-free stomach with associated complications, can also result from a regular use of proton pump inhibitor (PPI) medication.

In August 2020, a large study was published in Korea by Lee et al., according to which the use of PPI-medication leading to acid-free stomach also increases the risk of severe coronavirus infections.

It is well known that particularly among elderly people, acid-free stomach predisposes to severe and even fatal infections of the respiratory and gastrointestinal tract. Given this, there is a good reason to suspect that the patients with any of these health problems associated with acid-free stomach, might have a significantly increased risk of contracting and even die of coronavirus infection, as compared with the healthy population.

This is a global problem. Around one half of the world population are carriers of helicobacter infection, and in Finland, the best estimates are from 5% up to 70%, depending on the age. Helicobacter-induced atrophic gastritis (acid-free stomach) is encountered in about 500 million people worldwide. In addition to this, a long-term use of PPI-medication leads to acid-free stomach, with all potential clinical consequences.

Due to the reasons listed above, the novel international marketing strategy of the company is aiming i) at a significant increase in use of the GastroPanel test, that increases patient safety and leads to savings in health care costs, as well as ii) to implementation of the test as a supplement in coronavirus testing, particularly among the elderly risk group patients.

ColonView-FIT complements the GastroPanel-examination. In up to 50% of the people in the older age groups, the upper abdominal symptoms can be of intestinal origin. Consequently, it is recommended to use in the primary diagnosis of such symptom, the Biohit ColonView-FIT test (based on immunochemical principle), to diagnose the occult human blood (FOB) in the stool samples.

This test measures both human hemoglobin and hemoglobin-haptoglobin complex, being extremely sensitive, which makes ColonView-FIT highly suitable for the primary diagnosis and also as the test-of-choice in colorectal cancer screening. With the aid of this test, one can detect

colorectal cancer precursor lesions (adenomas and polyps), which enables timely referral of the patients for colonoscopy and other necessary examinations and therapy.

Acetium-capsules effectively bind, in acid-free stomach caused by helicobacter infection or PPI-medication, innate carcinogenic acetaldehyde which is a known important risk factor of gastric- and esophageal cancer. This invention has been granted a patent in over 40 countries.

By binding acetaldehyde, Acetium-capsules might reduce the risk of gastric- and esophageal cancer associated with acid-free stomach.

On the bases of the results from two clinical trials, it seems that Acetium capsules can also prevent the headache attacks in certain types of migraine.

Acetium lozenge facilitates smoking quit, and possibly alleviates also alcohol dependence. In addition, the lozenge promotes oral health by binding the smoke- and alcohol-derived carcinogenic acetaldehyde in the saliva. This invention has been granted a patent in 60 countries by now.

The challenge of the company during the coming years is not the lack of products or their potential markets. The true challenge is to reinforce both the domestic- and international marketing and the co-operation.

To conclude, I wholeheartedly also recommend as a further reading, the following document entitled: "Community accountability, patient safety and primary prevention" - (www.biohithealthcare.com/Links: Shareholders' meeting 2020)

Thank you so much for paying attention to the points raised above. By so doing, you could also give your personal input by spreading the message of the company concerning the offered possibilities to promote early detection and primary prevention of the risks of important diseases, both contributing to savings of health care costs and even human lives. This includes the possibility of supplementing coronavirus testing particularly among the risk groups of elderly subjects by the highly informative GastroPanel examination.

I conclude by wishing all participants and also other shareholders, good health and best success in your endeavours.

Osmo Suovaniemi

Chairman, Biohit Oyj

COMMUNITY ACCOUNTABILITY, PATIENT SAFETY AND PRIMARY PREVENTION OF DISEASES

As a result of the substantial community-responsible investments as well as innovation- and patenting strategy of Biohit Oyj (www.biohithealthcare.com /About Us/History: Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being), the company has introduced a series of products based on several innovations of the company. Such innovations that meet the major global need, increase patient safety and capable for primary prevention of diseases, include GastroPanel, ColonView-FIT and Acetium-series of products (www.biohithealthcare.com /Links: State of the art GastroPanel and Acetium innovations for the unmet need).

GastroPanel & GastroSoft (www.biohithealthcare.com / Links: GastroPanel innovation) (www.biohit.fi/additional-information) is a blood test for the first-line diagnosis in patients with upper abdominal symptoms and reflux complaints, and in addition, a highly informative test (capable of inducing substantial savings in the life-time health care costs) for screening of gastric- and esophageal cancer risk (www.gastropanel.com). According to the cost model designed by the Nordic Health Care Group (NHG), screening of the different risk factors of gastric- and esophageal cancer by GastroPanel test, would save the life-time health care costs of 10 age groups (eg 65-74-year-old) in Finland by over 800 million euro (<https://www.gastropanel.com/decision-makers/screening-model>).

ColonView-FIT: For the primary diagnosis of upper abdominal symptoms, of which up to 50% (particularly among elderly people) might be of intestinal origin, it is recommended to use the immunochemical ColonView-FIT-test for detection of fecal occult blood. This principle of immunochemical detection of human hemoglobin invented by the company founder in the early 1980's, has subsequently spread into global use (www.biohithealthcare.com/additional-information). Despite this fact, the national management guidelines published in 2019 entitled; "Dyspepsia and reflux symptoms", do not acknowledge the testing of fecal occult blood in the primary diagnosis of symptomatic patients. The highly sensitive ColonView-FIT measures both hemoglobin and hemoglobin-haptoglobin complex, is designed for the primary diagnosis, but is also highly suitable for colorectal cancer screening, detecting cancer precursor lesions (adenomas and polyps), thus facilitating the timely referral of the patients for colonoscopy and other appropriate examinations and treatment (www.colonview.com).

Acetium-capsules bind in acid-free stomach, resulting from atrophic gastritis or long-term use of PPI-medication, innate carcinogenic acetaldehyde, which is an important risk factor of gastric- and esophageal cancer. This invention has been granted a patent in over 40 countries until now. By eliminating carcinogenic acetaldehyde, Acetium capsules might reduce the risk of gastric- and esophageal cancer, associated with acid-free stomach (www.biohithealthcare.com /Links: State of the art GastroPanel and Acetium innovations for the unmet need).

Acetium-capsules can also prevent headache attacks in certain types of migraine

(www.biohithealthcare.com / Investors/Stock Exchange Press release: 2019-08-09T12:30:00Z – Biohit Oyj closes two clinical trials with Acetium® capsule for prevention of migraine-type headache).

Acetium lozenge helps quit smoking and possibly alleviate alcohol abuse and promote oral health by binding cigarette smoke- and alcohol-derived carcinogenic acetaldehyde in the saliva (This invention has been granted a patent in 60 countries) (www.acetium.com) (www.biohithealthcare.com/additional-information).

Population-based screening by Biohit GastroPanel® biomarkers practically eliminates the risk of gastric cancer during a long-term follow-up

A significant confirmatory evidence to the previous studies on GastroPanel® biomarkers as predictors of GC was provided by a recently published population-based screening study from the Republic of Karachaevo-Cherkessia (Russian Federation). In this longitudinal cohort study from the Department of Therapy, Medical Institute (North Caucasus State Academy for Humanities and Technologies, Cherkessk), Prof Kotelevets and his associates used a case-control setting by prospectively following-up two groups of subjects (n=2.220) for 7 years to monitor for the development of incident GC in these two groups (www.biohithealthcare.com / Investors/Stock Exchange and Press releases: 2020-03-12T08:00:00Z – Population-based screening by Biohit GastroPanel® biomarkers practically eliminates the risk of gastric cancer during a long-term follow-up) (www.biohithealthcare.com / Investors/Stock Exchange and Press releases: 2019-10-14T13:15:00Z – TREATMENT RECOMMENDATION IN RUSSIA: Use of GastroPanel® biomarkers should be used for detection of gastrointestinal diseases).

Already by the year 2006, the Finnish GastroPanel-innovation had been accepted into widespread use in several countries (www.biohithealthcare.com /Links : *Dear Colleague 2006* , the chapter “*Global evaluation of GastroPanel, its approvals and spreading use*”)

In the above referred review from 2006, the reader also finds an answer to the fact, why Finland is the only country in the world, where the national management guidelines “Dyspepsia and reflux symptoms” still specifically instruct that serological biomarker testing (GastroPanel) is not recommended in the primary diagnosis of dyspepsia and reflux symptoms, despite the fact this test detects, in addition to helicobacter infection, e.g. atrophic gastritis with increased risk of gastric cancer and other sequels (www.biohithealthcare.com/additional-information). Instead of GastroPanel, the management guidelines continue recommending (without admitting the prior errors and their incurred damage), the Helicobacter tests: 13C urea breath test (UBT) and stool antigen test (SAT), that do not detect atrophic gastritis with the risk of cancer and other severe sequels. This notwithstanding, the above referred management guidelines updated in 2019 do not launch a warning, among other things, about these severe shortcomings that endanger patient safety (www.biohithealthcare.com/Criticism-about-current-care-recommendations) (www.biohithealthcare.com /Links e.g: GastroPanel innovation). Together, this and the severe problem endangering patient safety, causing unnecessary health care costs for the community, and at the same time, severe long-term deleterious effects on Biohit Oyj, must be immediately remedied.

Does an undiagnosed atrophic gastritis (acid-free stomach) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?

Advanced age as such is not the only risk factor, but also the patient’s comorbidity increases the risk of coronavirus infection. One such potential risk group consists of elderly people who have atrophic gastritis (atrophy of stomach mucosa). Screening of the increased risks associated with acid-free stomach is possible by using the unique GastroPanel blood test developed by Biohit Oyj, that detects, in addition to helicobacter infection, also atrophic gastritis (acid-free stomach) and the state of gastric acid output (www.biohit.fi /Investors/Stock Exchange and Press releases: 2020-04-15T07:03:40Z –Does an undiagnosed atrophic gastritis (acid-free stomach) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?).

Asymptomatic atrophic gastritis that develops during the years of indolent course increasing along with the aging population, and bears an increased risk of gastric cancer and other sequels, remains without proper attention in the updated management guidelines of 2019: “Dyspepsia and reflux symptoms.” Unlike COVID-19, atrophic gastritis is not being feared as a severe disease because it is in most cases asymptomatic and the general public has not been properly informed about its character that frequently impairs quality of life and increases substantially the risk of cancer and even the risk of premature death. Particularly the elderly

people and their relatives have the right to know in time whether they are possibly affected by dementia, anemia or potentially cancerous atrophic gastritis that possibly also increases the risk of contracting coronavirus infection with an even fatal outcome.

In Finland, the population aging 70 years and above consists of around 875 000 people, of whom possibly 10-20% are bearers of atrophic gastritis, progressed during several years without diagnosis because asymptomatic in most cases, but associated with an increased risk of gastric- and esophageal cancer and other severe clinical sequels. Without correctly diagnosed helicobacter infection and/or timely detected atrophic gastritis, many patients can develop and even die of gastric- and esophageal cancer or in complications of bleeding Helicobacter-induced peptic ulcer disease. Atrophic gastritis is the major etiological course of vitamin-B12 deficiency, and the consequent diseases, including peripheral neuropathy, depression and dementia. Atrophic gastritis may also result in calcium deficiency, with consequent osteoporosis and bone fractures, as well as iron -deficiency anemia and its sequels. Along with the aging population, deficiency of vitamin-B12, calcium and iron have become an ever increasing national disease burden. Atrophic gastritis remaining undiagnosed by the UBT- and SAT-tests can also cause (particularly among elderly people) severe and even fatal infections of the gastrointestinal and respiratory tracts such as *Clostridium difficile*, *E. coli* EHEC and pneumonia. Prolonged high acid output will predispose to esophageal reflux disease, which can be accompanied by erosive esophagitis, Barrett's esophagus and lower esophageal cancer (www.biohithealthcare.com/additional-information).

The fact that the recommendations needed for early detection of atrophic gastritis and high acid output have been ignored in the updated 2019 management guidelines "Dyspepsia and reflux symptoms", which in addition, specifically recommends not to use in the primary diagnosis, the only test capable of timely detection of these conditions by serological biomarker assay (GastroPanel), explains in most part why out of the approximately 1000 annually diagnosed new patients with gastric- and esophageal cancer, some 700 will die of these diseases every year (average of 2 death every day). For comparison, coronavirus infection has caused 337 deaths in Finland since February 21, which translates also to 2 deaths per day.

Acid-free stomach combined with certain comorbidities might increase the risk of contracting coronavirus infection and its severity.

According to several international studies, untreated Helicobacter infection leads to acid-free stomach, (atrophic gastritis) associated with significantly increased risk of gastric cancer. Particularly among the elderly people, acid-free stomach also increases the risk of severe infections in the gastrointestinal- and respiratory tracts.

Approximately one half of the world population are bearers of helicobacter infection. In Finland, it is estimated that 5% up to 70% of the people have helicobacter, depending on the age. Helicobacter-induced atrophic gastritis is encountered among 500 million people, according to best estimates. As a comparison, over 28 million people have been infected by coronavirus, and until today, some 900 000 people have died of this infection. Around 1.6 million people are diagnosed with gastric- or esophageal cancer every year, and some 1.3 million patients die of these diseases annually.

Acid-free stomach increases, in addition to gastric cancer risk, also the exposure to severe gastrointestinal and respiratory infections This is important to keep in mind, while discussing about the risk groups of coronavirus infection. Until to date, this association between acid-free stomach and respiratory infections has not been addressed in the ongoing discussions.

Atrophic gastritis (and acid-free stomach) is in most cases asymptomatic, and consequently, its associated cancer risk remains frequently undiagnosed on time, causing potentially unnecessary cancer deaths

particularly among elderly people. In Finland, over 70% of the nearly 1000 annual gastric- and esophageal cancer patients will die of these diseases every year.

Furthermore, it is important to notice that acid-free stomach is also induced by prolonged use of proton pump inhibitor (PPI) medication. According to a recent large study published in August from Korea by Lee et al., the use of PPI-medication increases the risk of severe COVID-19 disease. These authors require caution to be practiced by the physicians while prescribing PPI-medication to their patients. Before continuing or starting a long-term PPI-medication, it is important to ensure that the patient does not already have an acid-free stomach as a result from atrophic gastritis, with all potential severe risks.

Coronavirus testing among elderly people should be accompanied by the test recognizing acid-free stomach

The patients suffering from asymptomatic, undiagnosed atrophic gastritis do have, in addition to increased cancer risk, also other problems that impair health and quality of life. These include e.g. deficiency of vitamin-B12, as well as malabsorption of iron, calcium, magnesium, zinc and some medicines. It can be estimated that among elderly people with these health problems, the risk of contracting also COVID-19 infection is significantly increased as compared with healthy population.

Biohit GastroPanel & GastroSoft-innovations detect Helicobacter infection and atrophic gastritis (with all associated risks), and give a reliable view on the state of gastric acid output. This simple blood test done in the laboratory is intended for the first-line early diagnosis of dyspeptic and reflux symptoms, as well as for the screening of gastric- and esophageal cancer risks. GastroPanel in diagnosis and screening help in timely detection of the subjects who need gastroscopy, therapy and follow-up. It should be also useful to combine GastroPanel with the coronavirus testing particularly among elderly people.

It is possible to reduce the risks associated with acid-free stomach, if atrophic gastritis is first recognized by GastroPanel test. Biohit Acetium[®]-capsules bind in acid-free stomach associated with atrophic gastritis or chronic use of PPI-medication, innate carcinogenic acetaldehyde which is considered among the chemical compounds increasing the risk of gastric cancer.

ADDITIONAL INFORMATION

1. www.biohithealthcare.com /Investors/Stock Exchange Releases: 2020-04-15T07:03:40Z – [Does an undiagnosed atrophic gastritis \(acid-free stomach\) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?](#)
2. Lee SW, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching Gut 2020;0:1–9. doi:10.1136/gutjnl-2020-322248
3. Stein RA. COVID-19: Risk groups, mechanistic insights and challenges. Int J Clin Pract. 2020;74:e13512
4. Koivurova, O-P., Ukkola, O., Koivikko, M., Ebeling, T., Yliaska, I., Koskela, R., Blomster, T., Ala-Rämi, A., Kettunen, O., Karttunen, T.J., Mäkinen, M., Ronkainen, J. and Syrjänen, K. Screening of the patients with autoimmune thyroid disease (AITD) and type 1 diabetes mellitus (DM1) for atrophic gastritis (AG) by serological biomarker testing (GastroPanel[®]). EC Gastroenterol. Digest. Syst. 7(8), 00-00, 2020.
5. Syrjänen K, Eskelinen M, Peetsalu A, Sillakivi T, Sipponen P, Härkönen M, Paloheimo L, Mäki M, Tiusanen T, Suovaniemi O, DiMario F, Fan ZP. GastroPanel[®] Biomarker Panel: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. A critical review. Anticancer Res 2019;39:1091-1104.
6. Syrjänen K: A Panel of serum biomarkers (GastroPanel[®]) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis. Anticancer Res 2016;36: 5133-5144.

7. Agreus L, Kuipers EJ, Kupcinskas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. *Scand J Gastroenterol* 47,136-147, 2012.

8. <https://www.gastropanel.com/decision-makers/screening-model> - In addition to the diagnostic use, it is recommended to screen the risk of gastric- and esophageal cancer by GastroPanel®-testing, which, according to the modelling designed by the Nordic Healthcare Group (NHG) saves the life-time health care costs of eg 10 age groups (65-74-year-old) in Finland, by over € 800 million.

9. Worldwide, 28 million people have been infected by coronavirus, and 900 000 have died of this disease. Helicobacter infection is encountered in half of the world population, and the resulting atrophic gastritis possibly in 500 million people. Acid-free stomach associated with atrophic gastritis or chronic use of PPI-medication with severe risks possibly exists in one billion people, whose risk of gastric- and esophageal cancer can possibly be reduced with Acetium®-capsules that bind carcinogenic acetaldehyde in the acid-free stomach (www.acetium.com, 10,11). Every year, some 1.6 million people develop gastric- or stomach cancer, and approximately 1.3 million patients die of it, of whom the majority could be preventable by early detection of Helicobacter, atrophic gastritis and high acid output (with related risks) by GastroPanel®-diagnosis and screening (www.biohithealthcare.com/additional-information , www.gastropanel.com , • www.biohithealthcare.com/test-request-form).

10. www.biohithealthcare.com / Investors/Stock Exchange Releases: 2017-09-11T07:30:00Z – [An important patent granted to Biohit Acetium® Capsule in Japan](#)

11. Jeong Soo Ahn, Chun-Sick Eom, Christie Y Jeon, Sang Min Park. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. *World J Gastroenterol* 2013 April 28; 19(16): 2560-2568.

12. www.biohithealthcare.com /Links e.g: GastroPanel innovaation

13. www.biohithealthcare.com/Criticism-about-current-care-recommendations